Technologies for Monoclonal Antibody Discovery and Development
International Journal of Molecular Sciences · 28.10.2025 · 26 (21) · 10470
DOI: 10.3390/ijms262110470 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.10.2025. Verfasst von Kyung Ho Han und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences and Biotechnology, Hannam University, Daejeon 34054, Republic of Korea. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Drug Discovery. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Medical University Yingcai Scholar Fund, Ministry of Education (MOE) in Taiwan, MOE Taiwan scholarship program.
Abstract (Originalsprache)
Monoclonal antibodies (mAbs) represent one of the most successful classes of biopharmaceuticals, with more than 100 approved for treating oncological, immunological, and infectious diseases. Antibody discovery and development have been driven by diverse methodologies. Classical strategies such as mouse hybridoma technology, phage display, transgenic mouse models, and single B cell isolation have enabled the generation of high-affinity therapeutic antibodies. Beyond binding affinity, recent innovations in combinatorial antibody libraries have facilitated the selection of functional antibodies within cellular environments, revealing their ability to act as agonists or antagonists and influence signal transduction pathways. These insights expand therapeutic applications by enabling modulation of complex cellular responses. Recent breakthroughs in artificial intelligence, involving antibody generation supported by rapidly growing antibody sequence and structure databases, are transforming computational protein design. This review highlights five major approaches (hybridoma technology, phage display, transgenic mouse models, and single B cell isolation, de novo antibody design) for antibody discovery and development. These approaches offer innovative strategies designed to accelerate the discovery process and enhance therapeutic outcomes for human diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences and Biotechnology, Hannam University, Daejeon 34054, Republic of Korea.
- Department of Biological Science and Technology, China Medical University, Taichung 406040, Taiwan.
- Cancer Biology and Precision Therapeutics Center, China Medical University, Taichung 406040, Taiwan.
- International Master Program of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan.
- Graduate Institute of Biological Science and Technology, China Medical University, Taichung 406040, Taiwan.
- Institute of Biochemistry and Molecular Biology, China Medical University, Taichung 406040, Taiwan.
ORCID-Profile: Kyung Ho Han
Förderung
- China Medical University Yingcai Scholar Fund
- Ministry of Education (MOE) in Taiwan
- MOE Taiwan scholarship program
- 2025 Hannam University Research Fund
Zitieren
APA
Han, K. H., Li, Y. C., Parveen, R., Venkataraman, S., & Lin, C. W. (2025). Technologies for Monoclonal Antibody Discovery and Development. International Journal of Molecular Sciences, 26(21), 10470. https://doi.org/10.3390/ijms262110470
Vancouver
Han KH, Li YC, Parveen R, Venkataraman S, Lin CW. Technologies for Monoclonal Antibody Discovery and Development. International Journal of Molecular Sciences. 2025;26(21):10470. doi:10.3390/ijms262110470
BibTeX
@article{Han2025,
author = {Han, Kyung Ho and Li, Yi-Chuan and Parveen, Rabia and Venkataraman, Srimathi and Lin, Chih-Wei},
title = {Technologies for Monoclonal Antibody Discovery and Development},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {21},
pages = {10470},
doi = {10.3390/ijms262110470}
}
EUVIMED